World Post Reporter
SEE OTHER BRANDS

Your global issues news reporter

World Post Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Post Reporter.

Press releases published on March 31, 2025

Rekor Systems Reports Strong 2024 Financial Results Highlighted by Record Revenue and Significant Operational Improvements

Rekor Systems Reports Strong 2024 Financial Results Highlighted by Record Revenue and Significant Operational Improvements

Record Gross Revenue: Achieved record annual gross revenue of $46.0 million, representing a 32% increase from $34.9 million in 2023. Fourth Quarter Results: Gross revenue reached an all-time quarterly high of $13.3 million in Q4 2024, marking a 20% …

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; …

World’s First: NOCCI and ERIC Introduce Dimensional Energy Work to Activate the Pineal Gland and Awaken the Third Eye

World’s First: NOCCI and ERIC Introduce Dimensional Energy Work to Activate the Pineal Gland and Awaken the Third Eye

A Breakthrough in Human Consciousness: Remote Energy Work Unlocks the Third Eye and Initiates Dimensional Contact MUNICH, BAVARIA, GERMANY, March 31, 2025 /⁨EINPresswire.com⁩/ -- International spiritual leaders NOCCI and her soul partner ERIC have co- …

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

         Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027 Strengthened cash position expected to support the Company through first substantive data readout in …

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases …

Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows

Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows

BOSTON and ATHENS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the Company’s Co-Founder and Chief Scientific Officer, Dr. …

Progress Announces First Quarter 2025 Financial Results

Progress Announces First Quarter 2025 Financial Results

Annualized Recurring Revenue ("ARR") of $836 million Grew 48% year-over-year Revenue of $238 million Grew 29% year-over-year ShareFile Integration Underway BURLINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Progress (Nasdaq: PRGS), the trusted provider …

Revolution Medicines to Participate in April 2025 Investor Conferences

Revolution Medicines to Participate in April 2025 Investor Conferences

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., …

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma (≥300 eosinophils/µL) receiving rademikibart for 24 weeks, …

Expion360 Reports Fourth Quarter and Full Year 2024 Financial Results

Expion360 Reports Fourth Quarter and Full Year 2024 Financial Results

Q4 Sequential Revenue Growth of 43% Driven by New Products and Technologies, and 131% Year over Year New OEM and Distributor Relationships to Equip New Campers and RVs with Advanced Lithium-Ion Batteries Began Shipping e360 Home Energy Storage Solutions …

Pathfinder Bancorp, Inc. Declares Dividend

Pathfinder Bancorp, Inc. Declares Dividend

OSWEGO, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- James A. Dowd, President and CEO of Pathfinder Bancorp, Inc., the bank holding company of Pathfinder Bank (NASDAQ: PBHC) (listing: PathBcp), has announced that the Company has declared a cash dividend of $0. …

Applied Digital Sets Fiscal Third Quarter 2025 Conference Call for Monday, April 14, 2025, at 5:00 p.m. Eastern Time

Applied Digital Sets Fiscal Third Quarter 2025 Conference Call for Monday, April 14, 2025, at 5:00 p.m. Eastern Time

DALLAS, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD) ("Applied Digital" or the "Company"), a designer, builder, and operator of next-generation digital infrastructure designed for High-Performance Computing (HPC) …

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral …

Birchtech Reports Fourth Quarter 2024 Financial Results

Birchtech Reports Fourth Quarter 2024 Financial Results

Company Drives Fourth Quarter 2024 Revenues of $5.6 Million; Leverages World-Class Activated Carbon Expertise to Launch New Water Purification Business CORSICANA, Texas, March 31, 2025 (GLOBE NEWSWIRE) -- Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) (" …

Aqua Metals Reports Milestone Advancements, Strategic Progress, and Sierra ARC Lithium Battery Recycling Campus Developments in 2024

Aqua Metals Reports Milestone Advancements, Strategic Progress, and Sierra ARC Lithium Battery Recycling Campus Developments in 2024

RENO, Nev., March 31, 2025 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium battery recycling, today announced key achievements from 2024 and outlined progress for 2025 as the Company delivered critical technical …

MDB Capital Holdings Provides Fourth Quarter and Full Year 2024 Update

MDB Capital Holdings Provides Fourth Quarter and Full Year 2024 Update

Addison, TX, March 31, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to …

Equity Stock Transfer teams up with Newsmax Inc. for historic IPO opening on New York Stock Exchange’s main board

Equity Stock Transfer teams up with Newsmax Inc. for historic IPO opening on New York Stock Exchange’s main board

New York, NY, March 31, 2025 (GLOBE NEWSWIRE) -- Equity Stock Transfer, LLC, a fully independent SEC registered transfer agent, today announced it is processing nearly 25,000 separate transaction requests from Newsmax investors through DRS (the direct …

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based …

Open Lending Reports Fourth Quarter and Full Year 2024 Financial Results

Open Lending Reports Fourth Quarter and Full Year 2024 Financial Results

AUSTIN, Texas, March 31, 2025 (GLOBE NEWSWIRE) -- Open Lending Corporation (Nasdaq: LPRO) (the “Company” or “Open Lending”), an industry trailblazer in lending enablement and risk analytics solutions for financial institutions, today reported financial …

INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results

INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results

- Infrastructure: DBM Global fourth quarter revenue of $225.7 million - - Life Sciences: MediBeacon® Transdermal GFR (“TGFR”) system received FDA approval to assess kidney function - - Spectrum: Broadcasting achieved double-digit revenue growth in the …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service